ETST Earth Science Tech

Earth Science Tech, Inc. Announces Official Name of MSN-2 Medical Device

Earth Science Tech, Inc. Announces Official Name of MSN-2 Medical Device

DORAL, Florida , July 05, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, is pleased to announce the brand name of its innovative MSN-2 medical device.

, the Company has been working to select a brand name for its MSN-2 medical device. The name that has been selected for  ETST’s leading-edge STI self-sampling kit for women is Hygee, which is the French name for the Goddess of Health and the word for “hygiene” in Greek mythology. While the French name is spelled with an acute accent on the first  “e” (é), the accent will not be used in the brand name.  The pronunciation of the name will be high-GEE in all markets worldwide. The marketing team, with the help of Absolu Communications, chose the name to reflect the product’s dedication to women’s health.

“We are very pleased with the work that Absolu has done on the name and on Hygee’s visual identity, including the logo design and the overall graphic signature of the product,” said Nickolas S. Tabraue, an president, director and chairman of ETST. “We anticipate that the registration of the trademark will be officially approved within 10 months, with a 90 percent chance of approval.”

In preparation for Hygee’s market introduction, a pre-launch clinical study is currently being conducted with Clinique Santé Amitié in Québec, Canada. The results will be announced in the near future.

The Company plans to share further updates on  its medical device, Hygee; on research and development; and on the Form 10 approval process as each progresses.

About Earth Science Tech, Inc. (ETST)

Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to  studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.

To learn more, please visit:  

ETST currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

Earth Science Pharmaceutical

Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharma, Inc. ("ESP"), which is committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.

To learn more please visit:  

Cannabis Therapeutics

Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs.

To learn more please visit:  

KannaBidioiD

KannaBidioid, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioiD, Inc. (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

To learn more please visit:  

Earth Science Foundation, Inc.

Earth Science Foundation, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Earth Science Foundation, Inc. ("ESF"), is in the process of becoming a tnonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech, Inc's effective CBD products to those in need.

To learn more please visit:    

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Dave Demarest 
305.546.7640 Office

Company Contact:
  
Nickolas S. Tabraue
President, Director, & Chariman
305.615.2118
EN
05/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Earth Science Tech

 PRESS RELEASE

Earth Science Tech, Inc. Announces Initiatives to Advance Public Compa...

Earth Science Tech, Inc. Announces Initiatives to Advance Public Company Strategy; Expects Approximately $1.4 Million in Annualized Savings and Fiscal 2026 Net Income Growth of More Than 40%, from $3.3 Million to $4.7 Million Outlines strategic portfolio actions, governance enhancements and capital discipline plans to support next phase of growth MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced that its Board of Director...

 PRESS RELEASE

Earth Science Tech, Inc. (ETST) Upgrades Audit Capabilities, Engages S...

Earth Science Tech, Inc. (ETST) Upgrades Audit Capabilities, Engages Semple, Marchal & Cooper, LLP as Independent PCAOB Auditor to Support Continued Expansion MIAMI, FL, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on a diversified, vertically integrated health and wellness portfolio, today announced the engagement of Semple, Marchal & Cooper, LLP (“Semple”) as its new independent Public Company Accounting Oversight Board (PCAOB) auditor. This transition represents a strategic upgrade in the Company’...

 PRESS RELEASE

Earth Science Tech, Inc. (ETST) Reports Third Fiscal Quarter 2026 Resu...

Earth Science Tech, Inc. (ETST) Reports Third Fiscal Quarter 2026 Results Revenue of $8.4 million, up 14.1% year-over-yearGross profit margin of 76.3%, up 71 bps year-over-yearNet income of $910,000, up 341% year-over-yearGenerated positive cash from operations of $1.2 million fiscal year-to-datePeaks, the company’s telemedicine platform, surpasses $2.0 million in revenue in less than a year, scaling from $248,000 into a high‑margin growth platformReduced outstanding shares of common stock by 3.6% year over year through share repurchasesGeographic expansion underway with up to 10 additional...

 PRESS RELEASE

Earth Science Tech, Inc. (ETST), to Report Financial Results for Fisca...

Earth Science Tech, Inc. (ETST), to Report Financial Results for Fiscal Third Quarter on February 17, 2026 MIAMI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced that it will report financial results for the three months ended December 31, 2025, after the close of trading on Tuesday, February 17, 2026. Investors with questions they would like addressed during the earnings call may submit them in advance at Conference Call In...

 PRESS RELEASE

Earth Science Tech, Inc. (ETST) Issues Directive Industry Classificati...

Earth Science Tech, Inc. (ETST) Issues Directive Industry Classification Update to SIC 2834; Formally Identifies as Pharmaceutical Entity Since 2022 MIAMI, FL, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company, is issuing a formal directive to all financial data providers, news aggregators, and brokerage platforms to reconcile their databases with the Company’s established pharmaceutical operations. Following a fundamental strategic pivot initiated in 2022, the Company has fully transitioned away from legacy indu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch